Sumi Thaker Appointed Chief Executive Officer of Gradientech
Sumi Thaker will assume the role of Chief Executive Officer at Gradientech on August 1, 2026. She will lead the company's growth and the commercialization of its QuickMIC platform.
Sumi Thaker has been appointed as the new Chief Executive Officer of Gradientech, effective August 1, 2026. Thaker will oversee the company's next phase of growth, focusing on accelerating the global commercialization of the QuickMIC antibiotic susceptibility testing platform.
She succeeds Sara Thorslund, a co-founder of Gradientech, who has led the company's development since 2009. Under Thorslund's leadership, Gradientech has evolved from an early-stage research concept into a clinically validated diagnostic platform.
The appointment signifies a strategic shift for Gradientech as it enters a new chapter of development and prepares for broader market penetration. The company's technology offers ultra-rapid antibiotic susceptibility testing, a critical tool for optimizing antibiotic treatment.
Gradientech aims to provide faster and more accurate diagnostic solutions for healthcare providers, potentially improving patient outcomes and reducing healthcare expenditures.